Τόμος 22 (2008) – Τεύχος 2 – Συμπλήρωμα 1 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Supplement 1 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. Dpt. of Cardiothoracic Anaesthesia and Intensive Care, James Cook University Hospital, Middlesbrough, UK

2. Pharmacy Dpt., Aretaieio University Hospital, Athens Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Sudlow G., Birkett D.J., Wade D.N.: The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11: 824-832 (1975)

3. Wanwimolruk S., Birkett D.J., Brooks P.M.: Structural requirements for drug binding to site II on human serum albumin. Mol. Pharmacol. 24: 458-63 (1983)

4. Foye W.O.: Principles of Medicinal Chemistry. 3rd Edition, p. 33, Lea and Febiger, Philadelphia, 1998

5. Olsen H., Andersen A., Nordbø A., Kongsgaard U.E., Børmer O.P.: Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro. BMC Clin. Pharmacol. 4: 4 (2004)

6. Prijovich Z.M., Leu Y.L., Roffler S.R.: Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer Chemother. Pharmacol. 60: 7-17 (2007)

7. Hu O.Y., Chu K.M., Liu H.S., Chiao S.F., Ho W., Ho S.T.: Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. Acta Anaesthesiol. Scand. 37: 258-261 (1993)

8. Birkett D.J., Myers S.P., Sudlow G.: Effects of fatty acids on two specific drug binding sites on human serum albumin. Mol. Pharmacol. 13: 987-992 (1977)

9. Vorum H., Honore B.: Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J. Pharm. Pharmacol. 48: 870-875 (1996)

10. Ivarsen R., Brodersen R.: Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid. Dev. Pharmacol. Ther. 12: 19-29 (1989)

11. Sansom L.N., Evans A.M.: What is the true clinical significance of plasma protein binding displacement inter-actions? Drug Saf. 12: 227-233 (1995)

12. Wosilait W.D., Ryan M.P.: The effects of oleic acid, tolbutamide, and oxyphenbutazone on the binding of warfarin by human serum albumin. Res. Commun. Chem. Pathol. Pharmacol. 25: 577-584 (1979)

13. Huang B.X., Dass C., Kim H.Y.: Probing conformational changes of human serum albumin due to unsaturated fatty acid binding by chemical cross-linking and mass spectrometry. Biochem J. 387(Pt 3): 695-702 (2005)

14. Urien S., Albengres E., Zini R., Tillement J.P.: Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein. Biochem. Pharmacol. 31: 3687-3689 (1982)

15. Holladay J.W., Dewey M.J., Michniak B.B., Wiltshire H., Halberg D.L., Weigl P., Liang Z., Halifax K., Lindup W.E., Back D.J.: Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab. Dispos. 29: 299-303 (2001)

16. Zhou H.H., Adedoyin A., Wilkinson G.R.: Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin. Pharmacol. Ther. 48: 10-17 (1990)

17. Belpaire F.M., Bogaert M.G., Mussche M.M.: Influence of acute renal failure on the protein binding of drugs in animals and in man. Eur. J. Clin. Pharmacol. 11: 27-32 (1977)

18. Henderson S.J.. Lindup, W.E.: Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin, Biochem. Pharmacol. 40: 2543-2548 (1990)

19. Viani A., Rizzo G., Carrai M., Pacifici G.M.: The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br. J. Clin. Pharmacol. 33: 299-304 (1992)

20. Cistola D.P., Small D.M.: Fatty acid distribution in systems modeling the normal and diabetic human circulation. A 13C nuclear magnetic resonance study. J. Clin. Invest. 87: 1431-1441 (1991)

21. Vorum H., Jorgensen H.R., Brodersen R.: Variation in the binding affinity of warfarin and phenprocoumon to human serum albumin in relation to surgery. Eur. J. Clin. Pharmacol. 44: 157-162 (1993)

22. Vorum H., Fisker K., Honore B.: Palmitate and stearate binding to human serum albumin. Determination of relative binding constants. J. Pept. Res. 49: 347-354 (1997)

23. Tsutsumi Y., Maruyama T., Takadate A., Goto M., Matsunaga H., Otagiri M.: Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin, Pharm. Res. 16: 916-923 (1999)

24. Sakai T., Yamasaki K., Sako T., Kragh-Hansen U., Suenaga A., Otagiri M.: Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm. Res. 18: 520-524 (2001)

25. Soltys B.J., Hsia J.C.: Steroid modulation of human serum albumin binding properties. A spin label study. J. Biol. Chem. 253: 4266-4269 (1978)

26. Bhattacharya A.A., Curry S., Franks N.P.: Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J. Biol. Chem. 275: 38731-38738 (2000)

27. Petitpas I., Grune T., Bhattacharya A.A., Curry S.: Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol. 314: 955-960 (2001)

28. Petersen C.E., Ha C.E., Curry S., Bhagavan N.V.: Probing the structure of the warfarin-binding site on human serum albumin using site-directed mutagenesis. Proteins 47: 116-125 (2002)

29. Tsopanakis C., Tesserommatis C.: Cold swimming stress: effects on serum lipids, lipoproteins and LCAT activity in male and female rats. Pharmacol. Biochem. Behav. 38: 813-816 (1991)

30. Tesserommatis C., Tsopanakis C., Varonos D.: Changes in serum lipids with the presence of various factors. Beitr. Infusionsther. 23: 195-197 (1988)

31. Saranteas T., Tesseromatis C., Potamianou A., Mourouzis C., Varonos D.: Stress-induced lidocaine modification in serum and tissues. Eur. J. Drug Metab. Pharmacokinet. 27: 229-232 (2002)

32. Tesseromatis C., Trichilis A., Tsivos E., Messari J., Triantaphyllidis H., Varonos D.D.: Does stress influence ampicillin concentration in serum and tissues? Eur. J. Drug Metab. Pharmacokinet. 26: 167-171 (2001)

33. Tesserommatis C., Tsopanakis C., Symeonoglou G., Loukissa M., Kouvarou E., Varonos D.D.: How harmless is FFA enhancement? Eur. J. Drug Metab. Pharmacokinet. 21: 213 (1996)

34. Trichilis A., Saranteas T., Potamianou A., Mourouzis C., Tesseromatis C.: Quinolone levels in serum and maxillofacial tissues under ibuprofen co-administration following surgical trauma. J. Musculoskelet. Neuronal Interact. 3:170-175 (2003)

35. Trichilis A., Tesserommatis C., Varonos D.: Changes in serum levels of quinolones in rats under the influence of experimental trauma. Eur. J. Drug Metab. Pharmacokinet. 25: 73-78 (2000)

36. Saranteas T., Zotos N., Lolis E., Stranomiti J., Mour-ouzis C., Chantzi C., Tesseromatis C.: Mechanisms of ketamine action on lipid metabolism in rats. Eur. J. Anaesthesiol. 22: 222-226 (2005)

37. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S.: Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 353: 38-52 (2005)

38. Tigka E., Daskala I., Rallis G., Anagnostopoulou S., Tesseromatis C.: Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats. Eur. J. Drug Metab. Pharmacokinet. 30: 235-241 (2005)

39. Saranteas T., Zotos N., Chantzi C., Mourouzis C., Rallis G., Anagnostopoulou S., Tesseromatis C.: Ketamine-induced changes in metabolic and endocrine parameters of normal and 2-kidney 1-clip rats. Eur. J. Anaesthesiol. 22: 875-878 (2005)

40. Tillement J.P., Lhoste F., Giudicelli J.F.: Diseases and drug protein binding. Clin. Pharmacokinet. 3: 144-154 (1978)

41. Perucca E.: Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther. Drug Monit. 2: 331-344 ((1980)

42. Tsivou E., Melakopoulos I., Kotsiou A., Anagnostopoulou S., Tesseromatis C.: Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen. Eur. J. Drug Metab. Pharmacokinet. 30: 171-174 (2005)

43. Melakopoulos I., Tesseromatis C., Saranteas T., Karabinos I.: Changes of serum and tissue amoxicillin levels following chlorpromazine administration in rats. Anaerobe 3: 103-105 (1997)

44. Saranteas T., Mourouzis C., Dannis C., Alexopoulos C., Lolis E., Tesseromatis C.: Effect of various stress models on lidocaine pharmacokinetic properties in the mandible after masseter injection. J. Oral Maxillofac. Surg. 62: 858-862 (2004)

45. Kotsiou A., Tsamouri M., Anagnostopoulou S., Tzivras M., Vairactaris E., Tesseomatis C.: H3 Propranolol serum levels following lidocaine administration in rats with CCL4 induced liver damage. Eur. J. Drug Metab. Pharmacokinet. 31: 97-101 (2006)

46. Tesseromatis C., Kotsiou A., Tsagataki M., Tigka E., Vovou J., Alevizou A., Perisanidis C., Saranteas T., Karakitsos D., Karabinis A., Kostopanagiotou G.: In vitro binding of lidocaine to liver tissue under the influence of propranolol: another mechanism of interaction? Eur. J. Drug Metab. Pharmacokinet. 32: 213-217 (2007)

47. Fichtl B., Gerdsmeier W.: Increased plasma protein binding of propranolol in rabbits with acute renal failure. Life Sciences 28: 31-35 (1981)

48. Fichtl B.: The influence of renal failure on-drug binding in plasma and tissues. Nieren-und Hochdruckkrankheiten 19: 447-449 (1990)

49. Bree F., Houin G., Barre J., Moretti J.L., Wirquin V., Tillement J.P.: Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clin. Pharmacokinet. 11: 336-342 (1986)

50. Fichtl B., Nieciecki A., Walter K.: Tissue binding versus plasma binding of drugs: General principles and pharmacokinetic consequences. Adv. Drug Res. 20: 117-166 (1991)

51. Habig W.H., Pabst M.J., Fleischner G., Gatmaitan Z., Arias I.M., Jakoby W.B.: The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc. Natl. Acad. Sci. USA: 3879-3882 (1974)

52. Saranteas T., Mourouzis C., Koumoura F., Tesseromatis C.: Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues. J. Oral Maxillofac. Surg. 61: 604-607 (2003)

53. Tesseromatis C., Saranteas T., Chatzijanni E., Anagnostopoulou S., Cotsioiu A., Chazti C.: Modifications of clonidine binding to rabbit liver protein under the influence of non-steroid-anti-inflammatory drugs in vitro. Eur. J. Drug Metab. Pharmacokinet. 28: 245-247 (2003)

54. Fichtl B., Kurz H.: Binding of drugs to human muscle. Eur. J. Clin. Pharmacol. 14: 335-340 (1978)

55. Tesseromatis C., Fichtl B., Kurz H.: Binding of non-steroid anti-inflammatory drugs and warfarin to liver tissue of rabbits in vitro. Eur. J. Drug Metab. Pharmacokinet. 12: 161-167 (1987)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr